Search 

Synergus is a MedTech Consulting Company in Reimbursement & Health Economics and Quality & Regulatory

Synoste is a Finnish startup company that develops and will sell novel patient friendly medical solutions for treatment of skeletal deformities. The first target is a better device for the well known, but complication prone limb lengthening procedure, which is still extremely uncomfortable for the patient.  Synoste utilizes smart materials and introduces a less painful and precisely controllable treatment device that lowers the complication rate and enables faster recovery to normal life.

UK Trade and Investment offers free support and independent advice to Nordic companies looking to invest or locate in the UK.

The UK is home to the National Health Service (NHS) - the world’s largest publicly funded healthcare system, a hub for the development and delivery of new medicines and technologies and a proven research partner. The NHS provides access to a diverse patient population, eminent clinicians and first-class medical researchers, across the whole healthcare spectrum.

The UK is investing hundreds of millions pounds in new medical technology innovation and has a new access schemes which will put new technologies in NHS hospitals more quickly than ever before.

Meet with Mark Campbell, Associate Director, Medical Technology Evaluation Program, National Institute for Health and Clinical Excellence, UK

We offer impartial advice on where and how to set up a business in the UK,

• in-depth, tailored information, including advice on financing, recruitment and activities such as R&D, tax, human capital,

Assistance, via our Partnership Programme, in finding new partners and expanding your business,

• practical help in the field, including visits to suitable locations, finding business partners and accessing financial incentives,

Unisensor is seeking investors for the development, clinical evaluation and launch of a new instrument for antibiotic susceptibility testing.

Sepsis (blood poisoning) is a serious medical condition that in US alone kills more than 100,000 annually, surpassing the number of deaths from acute myocardial infarction (AMI), stroke, or cancer. Once detected, it is paramount to initiate the proper antibiotic therapy as soon as possible, since survival chance decrease by the hour. In addition septicaemia patients is a substantial economic burden to the hospital – according to one source up to 50.000 USD per patient. Traditional AST typically takes from 15-30 hours, and Unisensor has shown that this can be decreased to less than one hour by using our patented technology. This will not only increase the survival chance and reduce the costs, but also have the societal benefit, that the emergence of multi-resistant bacteria is reduced due to the earlier usage of the proper narrow-band antibiotic therapy.

To finance the instrument development, clinical evaluation and initial sales and marketing activities Unisensor is seeking investors to enter into a joint venture or or other financial collaboration or partnership.